Rituximab für die Therapie der membranösen Glomerulonephritis

Beck LH Jr, Bonegio RG, Lambeau G et al (2009) M‑type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361(1):11–21
Article CAS Google Scholar
Fervenza FC, Appel GB, Barbour SJ et al (2019) Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 381(1):36–46
Article CAS Google Scholar
Howman A, Chapman TL, Langdon MM et al (2013) Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 381(9868):744–751
Article CAS Google Scholar
Hoxha E, Thiele I, Zahner G et al (2014) Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol 25(6):1357–1366
Article CAS Google Scholar
Ruggenenti P, Debiec H, Ruggiero B et al (2015) Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol 26(10):2545–2558
Article CAS Google Scholar

Author information

III. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland
E. Hoxha

Authors

E. Hoxha
View author publications
You can also search for this author in PubMed Google Scholar

Correspondence to E. Hoxha.

E. Hoxha gibt an, dass kein Interessenkonflikt besteht.

T. Feldkamp, Kiel

J. Lutz, Mainz

L.T. Weber, Köln

Hoxha, E. Rituximab für die Therapie der membranösen Glomerulonephritis. Nephrologe 15, 110–111 (2020). https://doi.org/10.1007/s11560-019-00391-9

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.